Improved health-related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT-5 trial.

ABSTRACT:

Aims

In SURMOUNT-5, tirzepatide led to greater body weight (BW) reduction versus semaglutide in adults with obesity without T2D. Health-related quality of life (HRQoL) with tirzepatide versus semaglutide in SURMOUNT-5 was evaluated.

Materials and methods

This analysis included on-treatment data from participants who received ≥1 dose of tirzepatide or semaglutide at their maximum tolerated dose. Changes in prespecified Short Form-36 Health Survey Version 2 (SF-36v2) norm-based scores for the Physical Component Summary (PCS), Mental Component Summary (MCS), and each domain, Patient Health Questionnaire-9, and Patient Global Impression of Status for Physical Activity scores were assessed at Week 72. Post hoc analysis of changes in SF-36v2 scores in participants with limited bas

SUBMITTER: Shukla AP 

PROVIDER: S-EPMC12673425 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature